3-(benzyl(methyl)amino)-1-(furan-2-yl)propan-1-one | 861709-18-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(benzyl(methyl)amino)-1-(furan-2-yl)propan-1-one
• 英文别名: 2-(N-benzylmethyl)aminoethyl-2-furylketone；3-[Benzyl(methyl)amino]-1-(furan-2-yl)propan-1-one
• CAS: 861709-18-4
• 化学式: C₁₅H₁₇NO₂
• 分子量: 243.305
• InChiKey: QCFRFMCOBPJRBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  363.0±27.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  33.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(benzyl(methyl)amino)-1-(furan-2-yl)propan-1-one 在 C₈₃H₇₉Cl₄N₃O₂P₄Ru₃ 、 氢气 、 potassium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 25.0 ℃ 、2.0 MPa 条件下， 反应 12.0h， 以100%的产率得到(R)-(benzyl(methyl)amino)-1-(furan-2-yl)propan-1-ol
  参考文献：
  名称：

  Asymmetric hydrogenation of β-amino ketones with the bimetallic complex RuPHOX-Ru as the chiral catalyst

  摘要：

  一系列β-氨基酮的非对称氢化反应是使用双金属复合物（RuPHOX-Ru）作为手性催化剂进行的。几乎所有反应（在存在KOH的甲苯和水的混合溶剂系统中进行）均实现了定量转化，产物的对映体过剩率高达99.9%。RuPHOX-Ru催化剂对潮湿和空气具有稳定性。该程序具有成本低、环保和高效率的优点。在相对低的催化剂负载下（催化剂转化数 = 2000），可以以定量产率和高达99.9%的对映体过剩率获得氟西汀、托莫西汀和尼索西汀的关键中间体。这种方法为上述药物及其类似物的合成提供了一种有前景的替代方案。

  DOI：

  10.1039/c3ob40135a
• 作为产物：
  描述：

  2-乙酰基呋喃 、 聚合甲醛 、 N-甲基苄胺 在 盐酸 作用下， 以 水 、 异丙醇 为溶剂， 以58.5%的产率得到3-(benzyl(methyl)amino)-1-(furan-2-yl)propan-1-one
  参考文献：
  名称：

  Asymmetric hydrogenation of β-amino ketones with the bimetallic complex RuPHOX-Ru as the chiral catalyst

  摘要：

  一系列β-氨基酮的非对称氢化反应是使用双金属复合物（RuPHOX-Ru）作为手性催化剂进行的。几乎所有反应（在存在KOH的甲苯和水的混合溶剂系统中进行）均实现了定量转化，产物的对映体过剩率高达99.9%。RuPHOX-Ru催化剂对潮湿和空气具有稳定性。该程序具有成本低、环保和高效率的优点。在相对低的催化剂负载下（催化剂转化数 = 2000），可以以定量产率和高达99.9%的对映体过剩率获得氟西汀、托莫西汀和尼索西汀的关键中间体。这种方法为上述药物及其类似物的合成提供了一种有前景的替代方案。

  DOI：

  10.1039/c3ob40135a

文献信息

• PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME
  申请人：Mikoshiba Katsuhiko

  公开号：US20120277423A1

  公开（公告）日：2012-11-01

  The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R 1 is a substituted or unsubstituted aryl or heterocyclyl group, R 2 , R 3 , and R 4 are hydrogen atoms, n is 2, X is halogen, R 5 and R 6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R 5 and R 6 are not hydrogen atoms at the same time, or R 5 and R 6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

  本发明涉及：一种具有转谷氨酰胺酶抑制活性的酮化合物，由下式1、2或3表示： 其中R1是取代或未取代的芳基或杂环基团，R2、R3和R4是氢原子，n是2，X是卤素，R5和R6独立地表示氢原子或取代或未取代的C1-C10烷基、芳基或芳烷基团，其中R5和R6不同时为氢原子，或者R5和R6可以共同形成含氮原子（N）的饱和或未饱和的、取代或未取代的杂环基团；包含该化合物的蛋白质交联抑制剂；以及包含该化合物或蛋白质交联抑制剂的用于预防或治疗由蛋白质交联引起的疾病的组合物。
• SUBSTITUTED QUINOLINES AND THEIR USE AS MYCOBACTERIAL INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1711492B1

  公开（公告）日：2008-04-16
• QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1912649B1

  公开（公告）日：2012-10-10
• Novel mycobacterial inhibitors
  申请人：Guillemont Emile, Georges Jerome

  公开号：US20070082895A1

  公开（公告）日：2007-04-12

  The present invention relates to novel substituted quinoline derivatives according to the general formula (Ia) or the general formula (Ib) salts, quaternary amines, stereochemically isomeric forms, tautomeric forms and N-oxide forms thereof, wherein R 1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2, 3 or 4; R 2 is hydrogen, hydroxy, thio, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula R 3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; R 4 is hydrogen, alkyl or benzyl; R 5 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R 5 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; r is 1, 2, 3, 4 or 5; R 6 is hydrogen, alkyl, Ar or Het; R 7 is hydrogen or alkyl; R 8 is oxo; or R 7 and R 8 taken together form the radical CH═CH—N═; Z is CH 2 or C(═O). The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as M. tuberculosis, M. bovis, M. avium, M. smegmatis and M. marinum. Also claimed is a pharmaceutical composition containing a compound of the present invention, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
• Quinoline Derivatives as Antibacterial Agents
  申请人：Andries Koenraad Jozef Lodewijk Marcel

  公开号：US20080227775A1

  公开（公告）日：2008-09-18

  Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of Formula (Ia) or (Ib) a pharmaceutically acceptable acid or base addition salt thereof, a quaternary amine thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N-oxide form thereof, wherein R 1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2, 3 or 4; R 2 is hydrogen, hydroxy, thio, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula R 3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; R 4 is hydrogen, alkyl or benzyl; R 5 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R 5 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; r is 1, 2, 3, 4 or 5; R 6 is hydrogen, alkyl, Ar or Het; R 7 is hydrogen or alkyl; R 5 is oxo; or R 7 and R 5 together form the radical —CH═CH—N═; Z is CH 2 or C(═O).